Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TERMIS 2021 | The benefits of extracellular vesicle-based therapies

Marta Monguió-Tortajada, PhD, Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, discusses the advantages of using extracellular vesicles (EVs) in tissue-engineered therapies. EVs tend to require less stringent storage conditions and as they are not live, they are more stable compared to cellular therapies. They can also be formulated into a slow-release dosage, resulting in a lower dose required for administration, and in vivo models have demonstrated mesenchymal stem cell-derived EVs have an acceptable safety profile. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).